Cardiovascular · StatinRegulatory Approvalcommercialnear-term

Mankind Pharma's Rosuvastatin Calcium ANDA206603 Receives AP Status

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 8/5/2026, 12:30:28 PM

Assessment confidence: 68% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The FDA's grant of Abbreviated Approval status to Mankind Pharma for Rosuvastatin Calcium signifies increased competition in the statin market. This could lead to pricing pressures and market share shifts for existing players in the cardiovascular therapeutic area. Regulatory context from FDA (FDA AP — ROSUVASTATIN CALCIUM (SUPPL)) supports the near-term read. Assessment grounded in 27 ranked evidence items (13 high-relevance).

Strategic Assessment

Portfolio teams should assess the impact of this approval on market share and pricing strategies for existing statin products. The strongest clinical anchor is A Study of Bempedoic Acid/Ezetimibe/High-intensity Statin in Patients Without Cardiovascular Events (ClinicalTrials.gov), entity match (rosuvastatin). In Cardiovascular · Statin, 8 regulatory and 5 competitive items passed relevance filtering for Mankind Pharma.

Competitive Pressure

The most relevant competitive pressure comes from Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217) (Roche) — sponsor/company relevance (roche). Secondary pressure from Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217). This approval allows Mankind Pharma to market a generic version of Rosuvastatin, increasing competition in the statin market.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — ROSUVASTATIN CALCIUM (SUPPL) (FDA). Entity match (mankind pharma); Regulatory pathway relevance (nda).

Key Risks

Elevated medium regulatory exposure for Mankind Pharma could delay market entry or constrain labeling if agency review intensifies.
Clinical risk from ClinicalTrials.gov (Non-pharmacological Interventions for People With Mild Cognitive Impairment in the Community) could weigh on Mankind Pharma through efficacy or safety read-through uncertainty if follow-through weakens.

Key Opportunities

The entry of a generic version of Rosuvastatin may impact revenue streams and market positioning for current statin products, necessitating strategic adjustments in pricing and marketing.
Upside for Mankind Pharma may improve if Cost-effectiveness and budget impact of ezetimibe-atorvastatin single-pill combination versus free combination in Chinese adults with hypercholesterolemia. (PubMed) delivers favorable follow-through.
Portfolio teams should assess the impact of this approval on market share and pricing strategies for existing statin products.

What Would Change This Assessment

This becomes more urgent if Monitor market entry timing and pricing strategies of Mankind Pharma's Rosuvastatin Calcium.
Timeline shift beyond near term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — ROSUVASTATIN CALCIUM (SUPPL)
FDAhigh relevance
Entity match (mankind pharma); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — ROSUVASTATIN CALCIUM (SUPPL)
FDAhigh relevance
Entity match (rosuvastatin); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — ROSUVASTATIN CALCIUM (SUPPL)
FDAhigh relevance
Entity match (rosuvastatin); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — ROSUVASTATIN CALCIUM (SUPPL)
FDAhigh relevance
Entity match (rosuvastatin); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — ROSUVASTATIN CALCIUM (SUPPL)
FDAhigh relevance
Entity match (rosuvastatin); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — ROSUVASTATIN CALCIUM (SUPPL)
FDAhigh relevance
Entity match (rosuvastatin); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — ROSUVASTATIN CALCIUM (SUPPL)
FDAhigh relevance
Entity match (rosuvastatin); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — ROSUVASTATIN CALCIUM (SUPPL)
FDAhigh relevance
Entity match (rosuvastatin); Regulatory pathway relevance (nda)
FDA document
View source

A Study of Bempedoic Acid/Ezetimibe/High-intensity Statin in Patients Without Cardiovascular Events
ClinicalTrials.govhigh relevance
Entity match (rosuvastatin)
FDA document
View source
Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Novartis)
FDA document
View source
The Effect of Channa Striata and Curcuma Supplementation on Nutritional Status, Interleukin-6 Levels, and Quality of Life in Patients With Breast Cancer.
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Study to Investigate Pharmacokinetics, Safety, and Tolerability of B2227 Extended-Release Injectable Suspension and Vraylar® in Participants With Schizophrenia
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Relationship Between Clinical Status and Nerve Conduction Test Findings in Patients With Unilateral Hemiplegia
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Non-pharmacological Interventions for People With Mild Cognitive Impairment in the Community
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Validate the Effect of Calcium Oral Spray on Early Childhood Caries
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Hydrus® Microstent New Enrollment Post-Approval Study
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217)
Rochehigh relevance
Sponsor/company relevance (Roche)
FDA document
View source
Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217)
Rochehigh relevance
Sponsor/company relevance (Roche)
FDA document
View source
Roche's Elecsys® pTau217 Blood Test Receives CE Mark for Alzheimer's Diagnosis
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
Teva's Sugammadex Sodium Receives FDA Approval Status
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA Accepts BLA761147 for PEGFILGRASTIM-PCCG by Accord Biopharma
Humanexa Signalsmedium relevance
Moderate corpus alignment

Cost-effectiveness and budget impact of ezetimibe-atorvastatin single-pill combination versus free combination in Chinese adults with hypercholesterolemia.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Development and in vivo pharmacokinetic evaluation of a phospholipid complex self-nanoemulsifying drug delivery system (PLC-SNEDDS) for enhanced oral bioavailability of cannabidiol.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Sanguisorba officinalis L. polysaccharides: A review of structural characteristics, pharmacological activities, structure-activity relationships and applications.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Investigation of the pharmacodynamic material basis and mechanism of Gexia Zhuyu Decoction in the treatment of primary dysmenorrhea with qi stagnation and blood stasis based on Chinmedomics.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
An integrated approach combining transcriptomics, network pharmacology, and experimental validation are used to investigate the mechanism of Lonicerae Japonicae Flos and Forsythiae Fructus extracts ag
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Effect of oral calcium carbonate on uterine contractility: a pilot randomised controlled trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Mankind Pharma
Rosuvastatin

Commercial impact

medium

The entry of a generic version of Rosuvastatin may impact revenue streams and market positioning for current statin products, necessitating strategic adjustments in pricing and marketing.

Regulatory impact

medium

While the approval itself is a positive regulatory development for Mankind Pharma, it indicates a more competitive landscape that may influence future regulatory strategies for other companies in the statin category.

What to watch

Monitor market entry timing and pricing strategies of Mankind Pharma's Rosuvastatin Calcium.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.